Securities and Exchange Commission
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 24, 2006
Commission File Number: 333-57780
INTERCARE DX, INC.
(Exact name of registrants specified in its charter)
California 95-4304537
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
6201 Bristol Parkway
Culver City California 90230
(213) 627-8878 Fax: (310) 743-0581
(Address, Including Zip Code, And Telephone Number, Including Area Code,
Of Registrant's Principal Executive Offices)
1
SECTION 1. Registrant's Business and Operations Not Applicable
SECTION 2. Financial Information Not Applicable
SECTION 3. Securities and Trading Markets Not Applicable
SECTION 4. Matters Relating to Accountants and
Financial Statements Not Applicable
SECTION 5. Corporate governance and Management Not Applicable
SECTION 6. Reserved Not Applicable
SECTION 7. Regulation FD
On February 24, 2006, registrant issued a press release announcing that it has
initiated full commercialization of the Vasogram Technology and names a
renowned scientist as the chairman of the Scientific Advisory Board.
SECTION 8: Other Events Not Applicable
SECTION 9: Financial Statements and Exhibits Not Applicable
Exhibit 99.1
A Copy of press release announcing that registrant has initiated full
commercialization of the Vasogram Technology and names a renowned scientist
as the chairman of the Scientific Advisory Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
InterCare DX, Inc.
(Registrant)
Date: February 24, 2006 By:/s/ Anthony C. Dike
-------------------------
Anthony C. Dike
(Chairman, Chief Executive Officer)
2
Exhibit 99.1
FOR IMMEDIATE RELEASE: FRIDAY FEBRUARY 24, 2006
CONTACT: Anthony C. Dike, MD, Chairman &CEO
InterCare DX, Inc.
213-627-8878
www.intercare.com
-----------------
INTERCARE DX, INC. INITIATES FULL COMMERCIALIZATION OF THE VASOGRAM TECHNOLOGY
AND NAMES A RENOWNED SCIENTIST AS THE CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD
CULVER CITY, CALIFORNIA.-Anthony C. Dike, MD, Chairman and CEO of InterCare DX,
Inc. (OTC BB: ICCO), announced today the appointment of Emeritus Professor Jeff
Raines, as the Chairman of the Scientific Advisory Board for the Vasogram
Technology, which has now been officially introduced to the market after almost
one year of pilot testing of the product by InterCare DX, Inc, for patient and
healthcare providers acceptance.
Professor Raines, professional experience includes over forty years in academia,
having received a Doctorate degree in Mechanical Engineering from Massachusetts
Institute of Technology and Doctorate degree in medicine from Harvard Medical
School under an NIH MD/PhD Training Fellowship in 1972. He has an extensive
formal education in the areas of clinical cardiovascular medicine with surgical
exposure, engineering and research. Professor Raines is a Fellow of American
College of Cardiology. He has published extensively in the area of
Cardiovascular medicine. He holds seven acclaimed United States patents
for the Vasogram and Endogram technology. He most recently retired as a
Professor of Surgery from University of Miami, Florida, USA. His role in
InterCare will include working with the Research and Development division of
InterCare to continue to enhance and update the Vasogram Technology for both
United States and International commercialization.
"Current cardiovascular research has confirmed that heart attack, stroke, and
most forms of peripheral vascular disease are caused by abnormalities in the
arterial wall. Vasogram is a new technology that has been developed that
allows physicians to assess the status of the arterial wall. The test is rapid
and painless and can be performed with no risk in a physician's office. In
addition, the cost of the testing is competitive with other noninvasive
cardiovascular tests." Dike said
"For the first time, physicians will know how their patient's arteries compare
to healthy subjects of the same gender and age. Further, they will know how
their patient's arteries compare to subjects with known peripheral and coronary
disease, which is the direct cause of over one million deaths annually,
generating over $100 billion direct and $180 billion. indirect treatment costs
annually.
The Vasogram technology will be most helpful in identifying subjects at risk.
With this identification treatment will start early and outcomes will improve.
Finally, this testing will target subjects who will benefit from more expensive
and perhaps invasive testing." Dike continued.
Initial estimates for procedures involving Vasogram technology and total market
opportunity, as estimated by McKinsey & Company, is between $300 million and
$500 million of a total $1.4 billion market potential.
Potential users of the Vasogram Technology include primary care physicians,
cardiologists, vascular specialists, clinics, and hospitals." Dike further
said.
"Professor Raines brings to InterCare a wealth of Scientific experience and
contacts, that we believe will help InterCare emerge as one of the industry
leaders in the area of Cardiovascular Technology," said Dike. "We welcome Jeff
to InterCare DX family, and know that he will be a tremendous asset as we begin
officially to commercialize the Vasogram Technology worldwide," Dike said.
"I am very thrilled to be working with Dr. Dike and the InterCare team in
further developing new technologies in the field of cardiovascular medicine, as
well as enhancing the Vasogram technology thereby making my Vasogram dream a
reality.' Said Professor Raines
About InterCare DX
InterCare DX, Inc. an affiliate of Meridian Holdings, Inc.(OTCBB: MRDH),
developed and markets under an exclusive value-added reseller agreement with
Meridian Holdings, Inc., InterCare Clinical Explorer (ICE ), an innovative,
robust and totally scalable software application designed to integrate every
aspect of the healthcare enterprise. InterCare provides implementation and
support for the ICE , which is used to document and track inpatient and
outpatient diagnoses and treatment modalities in various healthcare
environments, ranging from individual practices to entire hospital systems. The
Company by initiating commercialization of the Vasogram Technology, will be one
of the few technology companies with a unique cardiovascular diagnostics device
in the market that is backed by extensive scientific studies and publications.
For more information about the company and its products and services, visit
www.intercare.com.
-------------
NOTE: Statements in this news release that are not purely historical are
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and any amendments thereto. Material that is forward-looking
may contain statements about expected future events and/or financial results
that are forward-looking in nature. Editors and investors are cautioned that
such forward-looking statements invoke risk and uncertainties that may cause the
Company's results to differ from such forward-looking statements. These include,
but are not limited to, economic, competitive, governmental, technological, and
other factors discussed in the statements and/or in the Company's filings with
the Securities and Exchange Commission.
3